Endocrinology, Diabetes News | Endocrine Treatment & Research
WEBA free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.
Tirzepatide for Diabetes Outperforms Long-Acting Insulin
WEB7 hours ago · Tirzepatide demonstrates greater efficacy than long-acting and ultra-long-acting insulin for managing type 2 diabetes, yielding greater improvements in glycemic control, weight loss, and cardiovascular risk factors, according to study results published in the International Journal of Obesity.. Researchers conducted a systematic review and meta-analysis to compare the efficacy and safety of ...
The 2024 Update to the American Diabetes Association Standards …
WEBJan 12, 2024 · The American Diabetes Association (ADA) has updated its guidelines for the “Standards of Care” for patients with diabetes. The report has been published in Diabetes Care.. In the 2024 update, the ADA focused on patient-centered care, person-first language, and updated screening and treatment approaches based on the latest clinical evidence.
Empagliflozin for Type 2 Diabetes Elicits Superior Cardiorenal …
WEBFebruary 28, 2024. Empagliflozin, compared with GLP-1RA, demonstrated improved cardiorenal outcomes among patients with type 2 diabetes. Empagliflozin vs cardioprotective glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks for major adverse cardiovascular events (MACEs) and other cardiorenal outcomes, according ...
Semaglutide Improves Prediabetic Glycemic Control
WEBOct 20, 2023 · 93% (>20%). According to the researchers, “More weight loss was associated with greater improvements in glycemic control, while effects on glycemic parameters seemed to approach maximum at ≥15% weight loss.”. Glycemic control was associated with greater semaglutide-induced weight loss among participants with obesity and prediabetes.
Albiglutide Therapy Reduces Cardiovascular Events in Type 2 …
WEBFeb 26, 2024 · Albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, reduces the risk of cardiovascular events among older adults with type 2 diabetes and cardiovascular disease, according to the results of a post-hoc analysis published in Diabetes Obesity and Metabolism.. In the Harmony Outcomes trial (ClinicalTrials.gov; Identifier: NCT02465515), albiglutide reduced the rate of major adverse ...
How Do GLP-1 Receptor Agonists, Like Ozempic or Mounjaro, Work?
WEBJun 14, 2024 · GLP-1 receptor agonists also bind to the GLP-1 receptors on certain neurons in the brain to decrease hunger and increase satiety. They have been shown to slow gastric emptying within the first hour of eating, resulting in the feeling of being full. Patients who use GLP-1 receptor agonists experience reduced appetite and hunger, lower preference ...
Once-Weekly Insulin Icodec Demonstrates Efficacious, Safe …
WEBJan 26, 2024 · Once-weekly insulin icodec vs once-daily basal insulin analogues is associated with greater glycated hemoglobin (HbA 1c) reductions and higher rates of HbA 1c target achievement among patients with type 2 diabetes, according to study findings published in Diabetes, Obesity and Metabolism.. Designed for once-weekly administration, insulin icodec is a novel basal insulin analogue that may ...
The 2023 Update to the American Diabetes Association’s …
WEBNote: The 2024 American Diabetes Association guideline summary is available here.. The American Diabetes Association (ADA) just published their yearly updated guidelines for the “Standards of Care in Diabetes” in Diabetes Care.. As new research and treatment options for patients with diabetes emerge, the standard …
Diabetes Remission Induced by Lifestyle Approaches and Glucose …
WEBSep 21, 2023 · Diabetes remission can be induced following an intensive 12-week metabolic intervention combining insulin glargine/lixisenatide, metformin, and lifestyle approaches, according to study results published in Diabetes, Obesity and Metabolism.. Several trials have assessed the effects of lifestyle changes and various combinations of glucose-lowering medications on diabetes remission among patients ...